OCREVUS
300mg/10mlOCREVUS300mg/10ml
OCREVUS (Ocrelizumab) 300mg/10ml is a humanized anti-CD20 monoclonal antibody for relapsing and primary progressive multiple sclerosis (PPMS).
Key Benefits
- First and only approved treatment for PPMS
- 46-47% relapse rate reduction vs IFNβ-1a in RMS
- Convenient twice-yearly (every 6 months) dosing
- Superior MRI outcomes — significant reduction in T1 Gd+ and new/enlarging T2 lesions
- Over 300,000 patients treated worldwide since 2017
Contact Us for Pricing
Get competitive wholesale pricing for OCREVUS 300mg/10ml. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How OCREVUS Works
Ocrelizumab is a humanized monoclonal antibody that selectively targets CD20-expressing B lymphocytes. It depletes CD20+ B cells through antibody-dependent cellular cytolysis (ADCC) and complement-dependent cytolysis (CDC), reducing the inflammatory and neurodegenerative processes driving MS.
About OCREVUS 300mg/10ml
OCREVUS (Ocrelizumab) 300mg/10ml by Roche/Genentech is a breakthrough humanized anti-CD20 monoclonal antibody that has transformed the treatment of multiple sclerosis. It is the first and only FDA-approved disease-modifying therapy for primary progressive MS (PPMS), based on the landmark ORATORIO trial. In two Phase III trials (OPERA I and OPERA II), Ocrevus demonstrated 46-47% reduction in annualized relapse rates compared to interferon beta-1a (Rebif) in relapsing MS. The convenience of twice-yearly dosing (every 6 months) has made it one of the most prescribed MS therapies worldwide, with over 300,000 patients treated since approval in 2017. As a licensed pharmaceutical supplier based in Turkey, we provide authentic Roche OCREVUS with complete cold chain handling, certificate of authenticity, and competitive wholesale pricing for hospitals, MS treatment centers, and pharmaceutical distributors worldwide.
Common Uses
- Relapsing forms of multiple sclerosis (RMS)
- Primary progressive multiple sclerosis (PPMS)
- Clinically isolated syndrome (CIS)
- Active secondary progressive MS
Dosage Information
Initial: 300mg IV on Day 1, then 300mg IV on Day 15. Subsequent: 600mg IV every 6 months (24 weeks). Infuse over 2.5-3.5 hours with required pre-medication. Monitor for 1 hour post-infusion.
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store at 2-8°C (36-46°F). Do not freeze or shake. Protect from light. After dilution in 0.9% NaCl: stable 24 hours at 2-8°C or 8 hours at room temperature including infusion time.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About OCREVUS
Find answers to common questions about ordering, pricing, and shipping.
Related Rheumatology & Immune Products
Explore more rheumatology & immune medications from our catalog
